Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer
Ekaterina B Kuznetsova1, Tatiana V Kekeeva1, Sergei S Larin2, Valeria V Zemlyakova1, Anastasiya V Khomyakova3, Olga V BabenkBabenko1, Marina V Nemtsova1, Dmitry V Zaletayev1, Vladimir V Strelnikov1
1 Research Centre for Medical Genetics, Russian Academy of Medical Sciences; Molecular Medicine Institute, I.M. Sechenov Moscow Medical Academy, Moscow, Russia
2 Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia
3 Molecular Medicine Institute, I.M. Sechenov Moscow Medical Academy, Moscow, Russia
|Date of Submission||23-Sep-2006|
|Date of Acceptance||04-May-2007|
|Date of Web Publication||04-May-2007|
Vladimir V Strelnikov
Research Centre for Medical Genetics, Russian Academy of Medical Sciences; Molecular Medicine Institute, I.M. Sechenov Moscow Medical Academy, Moscow
Source of Support: None, Conflict of Interest: None
Loss of BIN1 tumor suppressor expression is abundant in human cancer and its frequency exceeds that of genetic alterations, suggesting the role of epigenetic regulators (DNA methylation). BIN1 re-expression in the DU145 prostate cancer cell line after 5-aza-2'-deoxycytidine treatment was recently reported but no methylation of the BIN1 promoter CpG island was found in DU145.
Methylation-sensitive arbitrarily-primed PCR was used to detect genomic loci abnormally methylated in breast cancer. BIN1 CpG island fragment was identified among the differentially methylated loci as a result of direct sequencing of the methylation-sensitive arbitrarily-primed PCR product and subsequent BLAST alliance. BIN1 CpG island cancer related methylation in breast and prostate cancers was confirmed by bisulphite sequencing and its methylation frequency was evaluated by methylation sensitive PCR. Loss of heterozygosity analysis of the BIN1 region was performed with two introgenic and one closely adjacent extragenic microsatellite markers. BIN1 expression was evaluated by real-time RT-PCR.
We have identified a 3'-part of BIN1 promoter CpG island among the genomic loci abnormally methylated in breast cancer. The fragment proved to be methylated in 18/99 (18%) and 4/46 (9%) breast and prostate tumors, correspondingly, as well as in MCF7 and T47D breast cancer cell lines, but was never methylated in normal tissues and lymphocytes as well as in DU145 and LNCaP prostate cancer cell lines. The 5'-part of the CpG island revealed no methylation in all samples tested. BIN1 expression losses were detected in MCF7 and T47D cells and were characteristic of primary breast tumors (10/13; 77%), while loss of heterozygosity was a rare event in tissue samples (2/22 informative cases; 9%) and was ruled out for MCF7.
BIN1 promoter CpG island is composed of two parts differing drastically in the methylation patterns in cancer. This appears to be a common feature of cancer related genes and demands further functional significance exploration. Although we have found no evidence of the functional role of such a non-core methylation in BIN1 expression regulation, our data do not altogether rule this possibility out.
|How to cite this article:|
Kuznetsova EB, Kekeeva TV, Larin SS, Zemlyakova VV, Khomyakova AV, BabenkBabenko OV, Nemtsova MV, Zaletayev DV, Strelnikov VV. Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J Carcinog 2007;6:9
|How to cite this URL:|
Kuznetsova EB, Kekeeva TV, Larin SS, Zemlyakova VV, Khomyakova AV, BabenkBabenko OV, Nemtsova MV, Zaletayev DV, Strelnikov VV. Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J Carcinog [serial online] 2007 [cited 2017 Mar 29];6:9. Available from: http://www.carcinogenesis.com/text.asp?2007/6/1/9/42148
| Background|| |
BIN1 (Bridging integrator 1) is a ubiquitous adaptor protein with the features of a tumor suppressor mediating apoptosis by c-MYC . The BIN1 gene is located on chromosome 2q14 within a region reported to be deleted in 30% to 40% of breast carcinomas . Complete or partial losses of BIN1 contained in this region in breast and prostate cancers have been reported [3,4]. Structural analysis of the human BIN1 gene  has promoted characterization of its molecular pathology in cancer. Notwithstanding the findings of genetic alterations, including allelic deletions, of BIN1 in breast cancer (BC), their frequencies are not sufficient to be responsible for all the cases of BIN1 losses occurring at the level of protein and/or message, suggesting a role for epigenetic factors . As far as BIN1 promoter contains a CpG island , DNA methylation events that affect promoter activity offer a likely mechanism for epigenetic alteration in cancer. This suggestion is supported by the study of genes reactivation after treatment of prostate cancer cell lines with 5-aza-2'-deoxycytidine, in which reactivation of BIN1 was detected in the DU145 cells . Although this finding suggests an epigenetic mechanism of BIN1 inactivation, bisulphite sequencing of the corresponding CGI had demonstrated "low" methylation. Methylation-specific PCR on the samples of primary tumors had not been performed . By methylation-sensitive arbitrarily-primed PCR (MSe-AP-PCR) we have detected abnormal methylation of a fragment of BIN1 promoter region CGI in BC and studied its methylation patterns in primary breast and prostate cancer samples as well as in the MCF7 and T47D BC cell lines and DU145 and LNCaP prostate cancer cell lines.
| Methods|| |
Ninety-nine paired (tumor/control) primary breast cancer and 46 primary prostate cancer samples were obtained from the Blokhin Cancer Research Center and Gertsen Moscow Oncology Research Institute and frozen at -70° until use. MCF7 cells were cultured in minimum essential medium (Eagle) with 2 mM L-glutamine, 10% fetal bovine serum (all from HyClone, USA), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 100 u/ml penicillin, 100 ug/ml streptomycin, supplemented with 0.01 mg/ml bovine insulin (all from Invitrogen, USA). T47D cells were cultured in RPMI 1640 medium with 2 mM L-glutamine, 10% fetal bovine serum (all from HyClone, USA), 1.0 mM sodium pyruvate, supplemented with 0.2 Units/ml bovine insulin (all from Invitrogen, USA). DU145 cells were cultured in DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (HyClone, USA). LNCaP cells were cultured in RPMI (Gibco, USA) supplemented with 10% fetal bovine serum (HyClone, USA) and 5% heat-inactivated horse fetal serum (Gibco, USA). After reaching the confluent cells were washed with D-PBS and detached by Trypsin-EDTA (HyClone, USA). Collected cells were used for DNA, RNA isolation.
DNA extraction was performed by standard phenol/chloroform method after proteinase K treatment of the tissues (cells). Screening for CpG islands differentially methylated in tumor and control sample pairs was performed by the methylation-sensitive arbitrarily-primed PCR (MSe-AP-PCR) described in  with the only exclusion that the primers were not radioactively labeled. MSe-AP-PCR fragments were run in nondenaturing polyacrylamide gels, stained by silver nitrate, excised, reamplified, and underwent direct sequencing on the ABI310 analyser (Applied Biosystems, USA) after HpaII digestion. Genomic locations of the differentially methylated fragments were identified by BLAST analysis and PCR primers directed to the corresponding regions were designed [Table 1]. Loss of heterozygosity (LOH) analysis of the BIN1 region was performed with two introgenic and one closely adjacent extragenic microsatellite markers [Table 1]. Methylation sensitive PCR (MSe-PCR) and methylation specific sequencing protocols were described previously ; corresponding primer sets used in this study are listed in [Table 1] and their relative positions are depicted in [Figure 1].
RNA extraction was done with the Ribosole A kit (Interlabservice, Russia). Extracted total RNA underwent DNAse (Promega, USA) treatment at 37°C for 10 min with subsequent DNAse inactivation at 65°C for 5 min. Reverse transcription (RT) reaction was performed with the High Capacity cDNA Archive Kit (Applied Biosystems, USA). Real-time RT-PCR relative quantification of BIN1 expression in tumor/control pairs was performed on the ABI PRIZM 7000 SDS (Applied Biosystems, USA) with the provided TaqMan expression assays (BIN1, target, Hs00184913m1; 18s rRNA, endogenous control, Hs99999901s1; according to the Applied Biosystems TaqMan Gene Expression Assays nomenclature).
| Results|| |
We have identified the BIN1 promoter CGI fragment among those differentially methylated in BC and morphologically intact tissues revealed by MSe-AP-PCR. After direct sequencing of the MSe-AP-PCR product MSe-PCR primers were designed and its methylation status in control and BC samples estimated. Methylation frequency in BC samples was determined as 18/99 (18%) for primary tumors; methylated status was also revealed in MCF7 and T47D cells. MSe analyses of prostate cancer samples resulted in the methylation figures of 4/46 (9%). No methylation was detected in control, morphologically intact tissues and lymphocytes as well as in DU145 and LNCaP prostate cancer cell lines.
Methylation-specific sequencing of the corresponding fragment has allowed us to evaluate the methylation status of every CpG pair within the locus of interest and to construct the methylation maps for 9 BC and 2 prostate cancer samples that showed methylated status by MSe-PCR [Figure 2], positions from +838 to +979). Of these, 7 samples demonstrated biallelic patterns of methylation of all the CpGs contained within the fragment, while in the rest all the CpG pairs were partially methylated which can reflect either monoallelic status of methylation or contamination of the tumor samples with normal cells. Sequencing of 9 control samples, as well as of the DU145 and LNCaP cells revealed no methylated CpGs within the region. Analysis of MCF7 BC cells showed biallelic pattern of methylation of all CpG pairs within the sequenced fragment, while in the T47D BC cells 5 proximal CpG pairs demonstrated biallelic methylation and 5 distal CpG pairs were partially methylated. [Figure 2].
BIN1 expression analysis revealed significant gene expression decrease/abrogation in 77% tumors (compared to apparently normal adjacent counterparts, 13 pairs tested), expression was completely arrested in the MCF7 cell line and 6-fold decreased in T47D compared to the control morphologically intact breast tissues [Figure 3]. LOH analysis using two intragenic and one closely adjacent extragenic markers has excluded BIN1 deletion (LOH) in MCF7 cells by revealing the heterozygous state of the BIN1 intron 1 trinucleotide (tcc)n repeat and of the (ca)n repeat 3 kb distal to the gene. In T47D cells only the latter was informative and demonstrated heterozygous state with presumable partial LOH detected by decrease of band intensity corresponding to one of the alleles. Observed frequency of BIN1 LOH in primary breast tumors was unexpectedly low: 81% (22/27) were informative for at least one of the three microsatellite markers elaborated and only in 9% (2/22) of those allelic loss was detected.
As far as the fragment detected as abnormally methylated by MSe-AP-PCR is located within the 3' region (intron 1) of BIN1 promoter CGI [Figure 1] and its methylation would conventionally be considered not to affect gene expression, we have constructed primers directed to the 5'-end of the same CGI in order to evaluate methylation that may have possible functional consequences. By the results of both MSe-PCR (30 samples) and methylation-specific sequencing (25 samples) this part of the CGI appeared to be completely unmethylated in tumor samples, in MCF7, T47D, DU145, LNCaP cell lines and in 10 control samples.
| Discussion|| |
Altered expression of the tumor suppressor BIN1 in various cancers had been previously reported in a number of papers. Sakamuro et al. reported significant reduction or complete loss of its expression in 14/27 BC cell lines including MCF7 and T47D as well as in 3/6 primary breast tumors by Northern analysis . Complete or partial loss of BIN1 was reported in 6/6 estrogen receptor-positive and estrogen receptor-negative breast carcinoma cell lines and in 30/50 (60%) samples of malignant breast tissue analyzed by immuno-histochemistry or RT-PCR . BIN1 mRNA was decreased in 25%, and lost in 67% of 24 breast cancer specimens in the study of Deng et al. . RNA and immunohistochemical analyses indicate that BIN1 is expressed in most primary prostate tumors, even at slightly elevated levels relative to benign tissues, but that it is frequently missing or inactivated by aberrant splicing in metastatic tumors and androgen-independent tumor cell lines . Genetic causes of BIN1 inactivation in prostate cancer mostly occur as a result of allelic losses . The frequency of BIN1 losses exceeds the frequency of so far identified genetic alterations, suggesting a role for epigenetic factors . One of these is BIN1 mRNA aberrant splicing detected in melanoma and prostate cancer [4,10]. Another likely mechanism for BIN1 epigenetic alteration might be presented by DNA methylation events that affect promoter activity . The BIN1 promoter contains a CpG island ; nevertheless, we failed to find any report of a targeted methylation study of this region. Scarce information comes from the screening studies aimed to detect typical epigenetic alterations in cancer. Thus, Lodygin et al. report reactivation of BIN1 in one of the three prostate cancer cell lines, DU145, after 5-aza-2'-deoxycytidine treatment which suggested epigenetic regulation of the gene expression by promoter methylation. Based on the bisulphite sequencing methylation of BIN1 promoter in DU145 was classified as low, and methylation analyses in primary tumors have not been performed .
We have identified a fragment of BIN1 5'-CGI among those differentially methylated in BC by MSe-AP-PCR. Significant methylation levels of the corresponding region in breast and prostate primary tumors and its methylated status in MCF7 and T47D BC cells accompanied by a high frequency of decreased/abrogated expression of BIN1 in our cancer samples suggested possible involvement of methylation in BIN1 expression regulation.
Promoter CGIs often span more than 1 kilobase, and their methylation status is as a rule heterogeneous. Methylation often occurs in downstream regions of the promoter CGIs, but it is believed not to repress transcription [11,12]. Thus, the CDKN2A gene promoter CGI spans the promoter region and exon 1, but its transcription is only consistently repressed when a 230-bp region that covers the transcription start site is methylated . RASSF1A also contains a promoter CGI that continues into its first exon, but methylation of a region covering the minimal promoter is enough for the loss of its expression . MLH1 has a large promoter CGI that initiates at nucleotide -1,000 and extends throughout exon 1. Its methylation has been observed in far upstream regions, but only the methylation of a 280-bp region covering the transcription start site is correlated with transcription repression [14,15].
BIN1 promoter CGI spans 1650 bp of genomic sequence including 5'-upstream region, exon 1 and a fragment of intron 1 of the gene and obviously contains both promoter and nonpromoter sequences. Structural and functional analysis of a ~0.9 kb 5'-sequence adjacent to exon 1 had revealed that it contains consensus sites for several transcription factors and is sufficient for basal transcription of BIN1 . As far as the promoter CGI fragment initially identified and analyzed in our study lies within intron 1 of the gene and does not belong to the promoter, to evaluate possible methylation of the genuine promoter region we have designed the sets of MSe and MSp primers directed to the corresponding locus. Surprisingly, but in consistence with the data presented by Lodygin et al. , we failed to detect its abnormal methylation even in the tumor samples methylated throughout the 3'-part of the promoter CGI. We suggest that BIN1 promoter CGI, similarly to those of CDKN2A or RASSF1A genes, is composed of the two functionally unequal parts, 3' being frequently and densely methylated and 5' being lowly methylated in cancer. This statement has two major concequences. On one side, as far as we have shown that the methylation of the 3'-part is cancer-specific, it can be elaborated in the development of epigenetic cancer markers after thorough evaluation of its methylation patterns in different types of tumors. On the other, the methylation analysis of the 3'-part may not be used in the functional studies (may not be taken as the evidence of expression loss) so far, as a priori assumption is that it is not likely to affect gene expression. It should be noted though, that the absence of such a functional link is to be supported by further exploration, which may altogether prove the opposite. Previously the analysis of more than 30 silenced genes and 100 non-silenced genes showed that methylation of only a relatively small 'core' region covering the transcription start site is consistently associated with gene silencing [16,17]. It has not yet been established, however, whether or not the core region should always contain the minimum promoter and the transcription start site .
| Conclusion|| |
Our study supports previously obtained data of frequent cancer-associated loss of BIN1 expression in breast cancer. LOH and CpG methylation analyses demonstrate that these events, being among the most widespread causes of genes' inactivation in cancer, are nevertheless not responsible for the majority of cases of BIN1 loss in BC. Even in the case of functional significance of the BIN1 CGI 3'-part methylation, it would account for 18% of expression losses only, and the frequency of LOH in our BC samples is even lower. One possibility, which was never tested, is that BIN1 is downregulated in BC by alternative splicing like it is in prostate cancer and melanoma. Another one derives from the demethylation activation assay  and our methylation study on DU145 cells: reactivation of BIN1 expression after 5-aza-2'-deoxycytidine treatment in the cells with unmethylated status of its CGI suggests the role for the upstream epigenetically regulated factors.
| Abbreviations|| |
BC - breast cancer; CGI - CpG island; MSe-PCR - methylation-sensitive PCR; MSe-AP-PCR - methylation-sensitive arbitrarily-primed PCR.
| Acknowledgements|| |
The study was supported in part by Applied Biosystems, USA.The publication charge has been covered by Applied Biosystems, USA.
| References|| |
|1.||Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC: BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996, 14 (1) : 69-77. |
|2.||Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, Birnbaum D: Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 1997, 57: 5469-5474. |
|3.||Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC: Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 2000, 85 (3) : 376-383. |
|4.||Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC: Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 2000, 86 (2) : 155-161. |
|5.||Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC: Structural Analysis of the Human BIN1 Gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J Biol Chem 1997, 272: 31453-31458. |
|6.||Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H: Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer. Cancer Res 2005, 65: 4218-4227. |
|7.||Liang G, Gonzalgo ML, Salem C, Jones PA: Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods 2002, 27 (2) : 150-155. |
|8.||Zemliakova VV, Strel'nikov VV, Zborovskaia IB, Balukova OV, Maiorova OA, Vasil'ev EV, Zaletaev DV, Nemtsova MV: Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia. Mol Biol (Mosk) 2004, 38 (6) : 966-972. |
|9.||Deng WH, Wu YY, Yang L, Tang WQ, Wang S: Expression of estrogen sulfotransferase (EST) gene and bridging integrator protein-1 (BIN1) gene and their significance in breast tissues. Ai Zheng 2004, 23 (11) : 1302-1305. |
|10.||Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC: Mechanism for elimination of a tumor suppressor: Aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. PNAS 1999, 96: 9689-9694. |
|11.||Tsutsumi M, Tsai YC, Gonzalgo ML, Nichols PW, Jones PA: Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. Oncogene 1998, 17 (23) : 3021-3027. |
|12.||Abe M, Okochi E, Kuramoto T, Kaneda A, Takato T, Sugimura T, Ushijima T: Cloning of the 5' upstream region of the rat p16 gene and its role in silencing. Jpn J Cancer Res 2002, 93 (10) : 1100-1106. |
|13.||Yan PS, Shi H, Rahmatpanah F, Hsiau TH-C, Hsiau AH-A, Leu Y-W, Liu JC, Huang TH-M: Differential Distribution of DNA Methylation within the RASSF1A CpG Island in Breast Cancer. Cancer Res 2003, 63: 6178-6186. |
|14.||Deng G, Chen A, Hong J, Chae HS, Kim YS: Methylation of CpG in a Small Region of the hMLH1 Promoter Invariably Correlates with the Absence of Gene Expression. Cancer Res 1999, 59: 2029-2033. |
|15.||Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K, Igarashi S, Kotake K, Koyama Y, Nagai H: Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001, 121 (6) : 1300-1309. |
|16.||Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T: Identification of Silencing of Nine Genes in Human Gastric Cancers. Cancer Res 2002, 62: 6645-6650. |
|17.||Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono K, Seki S, Fukushima S, Tsao MS, Sugimura T, Ushijima T: Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004, 23 (53) : 8705-8710. |
|18.||Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005, 5 (3) : 223-231. |
[Figure 1], [Figure 2], [Figure 3]
|This article has been cited by|
||Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
| ||George C. Prendergast,Courtney Smith,Sunil Thomas,Laura Mandik-Nayak,Lisa Laury-Kleintop,Richard Metz,Alexander J. Muller |
| ||Cancer Immunology, Immunotherapy. 2014; |
|[Pubmed] | [DOI]|
||Bridging integrator 1 (BIN1): form, function, and Alzheimerćs disease
| ||Meng-Shan Tan,Jin-Tai Yu,Lan Tan |
| ||Trends in Molecular Medicine. 2013; 19(10): 594 |
|[Pubmed] | [DOI]|
||Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
| ||Elizabeth S. McKenna,Pablo Tamayo,Yoon-Jae Cho,Erik J. Tillman,E. Lorena Mora-Blanco,Courtney G. Sansam,Edward C. Koellhoffer,Scott L. Pomeroy,Charles W.M. Roberts |
| ||Cell Cycle. 2012; 11(10): 1956 |
|[Pubmed] | [DOI]|
||MYC, PARP1, and chemoresistance: BIN there, done that?
| ||Ganesan, S. |
| ||Science Signaling. 2011; 4(166): art 15 |
|| DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer
| ||Samuelsson, J.K., Alonso, S., Yamamoto, F., Perucho, M. |
| ||Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2010; 693(1-2): 61-76 |
|| Novel tools for unbiased DNA differential methylation screening
| ||Tanas, A.S., Shkarupo, V.V., Kuznetsova, E.B., Zaletayev, D.V., Strelnikov, V.V. |
| ||Epigenomics. 2010; 2(2): 325-333 |
||Novel tools for unbiased DNA differential methylation screening
| ||Alexander S Tanas,Viktoria V Shkarupo,Ekaterina B Kuznetsova,Dmitry V Zaletayev,Vladimir V Strelnikov |
| ||Epigenomics. 2010; 2(2): 325 |
|[Pubmed] | [DOI]|
||Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: From biochemistry to clinical development
| ||Rutella, S., Bonanno, G., De Cristofano, R. |
| ||Endocrine, Metabolic and Immune Disorders - Drug Targets. 2009; 9(2): 151-177 |